Cellbion Co Ltd

Cellbion's capital structure shows a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to typical pharmaceutical firms. The company holds 1.96 billion KRW in cash and equivalents, but this is offset by 8.42 billion KRW in long-term debt, resulting in a net cash position of -6.46 billion KRW. The current ratio of 11.1 suggests strong short-term liquidity, with current assets significantly outpacing current liabilities. Profitability metrics reveal significant underperformance relative to industry norms. The company reported a net loss of 7.57 billion KRW and an operating loss of 8.24 billion KRW, resulting in a return on equity of -33.24% and return on assets of -21.52%. These figures are well below the typical positive returns seen in the pharmaceutical industry, indicating operational challenges and potential misalignment with industry_config preferred metrics. Segmental and geographic exposure data is not explicitly provided in the input, but the company's operations are disclosed to include pharmaceutical development, generic drugs, CDMO services, and cosmetics. Given the lack of geographic breakdown, it is unclear whether revenue is concentrated in specific regions or if the company has diversified exposure. Growth trajectory analysis shows a negative operating cash flow of 5.55 billion KRW and free cash flow of -8.37 billion KRW, with capital expenditures of -1.68 billion KRW. These figures suggest the company is investing in operations but is not generating positive cash flow, which could constrain future growth unless operational efficiency improves. Risk factors include medium liquidity risk due to negative net cash and a high current ratio, which may not be sustainable in the long term. Dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. However, the company's negative net income and operating cash flow could pressure future capital structure decisions. Recent events include the latest financial filing (HA-latest) disclosing the company's significant losses and liquidity position. No recent transcripts or filings beyond the financial snapshot are provided in the input data.